Policy Digest — May 4, 2026

Weekly Spotlight

Prior Authorization Reform Reaches an Inflection Point

Three converging tracks made this week notable for prior authorization (PA) policy. On the federal pressure side, Senator Maria Cantwell (D-WA) sent a formal letter on April 27 to HHS Secretary Robert F. Kennedy Jr. urging an overhaul of the Centers for Medicare and Medicaid Services’ (CMS) AI-driven prior authorization program, citing evidence that algorithmic denials in the Wasteful and Inappropriate Service Reduction (WISeR) demonstration are causing care delays and increased denial rates without adequate human oversight.

On the legislative track, a bipartisan group of House members, five of whom are also physicians, introduced legislation on April 20 that would impose stricter prior authorization timelines and tighter denial standards on Medicare Advantage (MA) plans. The bill comes amid growing congressional frustration with MA plan denials and would establish enforceable response timeframes that proponents argue are necessary to translate existing CMS rules into meaningful patient protections.

A voluntary industry track converged on the same goal from the opposite direction. Five major health insurers, including UnitedHealthcare, Aetna, Humana, and Cigna, jointly announced a commitment to standardize electronic prior authorization data submission requirements, creating a common framework intended to enable providers to submit a single PA request that is accepted across participating payers. Industry executives publicly touted progress on the framework as a response to mounting provider and policymaker pressure.

CMS added a regulatory track of its own. On April 14, CMS and the HHS Office of the National Coordinator for Health Information Technology published a proposed rule requiring impacted payers to make electronic prior authorization available for drugs and to expand interoperability standards, building on the agency’s earlier 2024 PA rule and extending its scope into the pharmacy benefit space.

The convergence is sharpened by an unusual critical voice. In a STAT News interview, Archelle Georgiou, a former chief medical officer at UnitedHealthcare who helped eliminate prior authorization for many services in the 1990s under CEO Bill McGuire, told STAT that prior authorization has “lost its original purpose” and now functions primarily as a cost-control lever rather than a tool for clinical appropriateness review. The simultaneity of federal pressure, bipartisan legislative action, voluntary industry commitment, regulatory expansion, and pointed insider criticism is unusual for a policy area that has been the subject of incremental reform efforts for years.

Tags: #PAYER #PROVIDER #PATIENT

Centers for Medicare and Medicaid Services (CMS)

HR 1 Medicaid Implementation Hits the Ground in Nebraska as Rural Hospitals Feel the Squeeze

The first practical implementation week of HR 1’s Medicaid provisions produced sharply uneven state activity and growing evidence of provider strain. Nebraska launched its work requirement on May 1, the first state in the country to do so, eight months ahead of the federal deadline, with between 20,000 and 40,000 enrollees expected to lose coverage. Nebraska’s exemption framework relies on a broad “medically frail” category that other states are watching closely. MACPAC opened debate on what data states must collect to support implementation; KFF Health News and Georgetown CCF analyses documented major divergence in state planning, with some states demanding more than the federal one-month minimum and others, including North Carolina, beginning to brace for casework volume. Rural hospitals reported that the law’s $50 billion Rural Health Transformation Fund is falling well short of offsetting the Medicaid coverage and revenue impact, and large companies are positioning to capture portions of fund disbursements as states stand up programs. CMS deferred another $91 million of Minnesota’s Medicaid funds in a separate compliance dispute. On the marketplace side, enrollees are now facing surprise tax increases as the megabill eliminated premium tax credit repayment caps, and SNAP participation has dropped at the steepest rate in decades following megabill cuts.

• Nebraska Is First State to Implement Medicaid Work Requirement
• Trump’s Medicaid Work Mandate Debuting in Nebraska to Much Dismay
• New Federal Medicaid Rules Require One Month of Work. Some States Demand More.
• MACPAC Debates Data Collection Recommendations for Work Requirements Implementation
• NC Braces for Medicaid Work Requirement Cases
• Rural Hospitals and Communities Feel Impact of H.R. 1 Medicaid Cuts as Rural Health Fund Falls Short
• Marketplace Enrollees Face Surprise Tax Increases After Megabill Eliminates Premium Tax Credit Repayment Caps
• Post-Megabill Drop in SNAP Participation Is Steepest in Decades
• CMS Defers Another $91 Million Of Minnesota’s Medicaid Funds
• Large Companies Position for $50 Billion Federal Rural Health Fund Disbursement

Tags: #PROVIDER #PAYER #PATIENT

Medicare Advantage in Flux: 2027 Final Rule, Elevance Reserves, and a DOJ Fraud Fight

Medicare Advantage (MA) was the most active payer space of the week. CMS finalized its 2027 MA rule, with KFF analysis finding that the rule strengthens some consumer protections—particularly around marketing practices and prior authorization timelines—while rolling back others, including certain supplemental benefit flexibilities. Elevance Health disclosed in its Q1 earnings that it set aside $935 million in reserves over a Medicare Advantage enrollment dispute with CMS. Separately, STAT reported that the Department of Justice and Elevance are sparring over DOJ access to a top Elevance executive in an MA fraud case, with the agency pushing for a key witness who has so far been kept from a deposition. The cluster of stories underscores the financial and legal stakes for MA plans as the 2027 rule changes take effect alongside increased federal scrutiny of plan billing practices.

Sources: KFF Health News, Becker’s Hospital Review, STAT News

Tags: #PAYER #PROVIDER

340B Pressure Builds: Lilly Threat, HRSA Pilot Splits Stakeholders, North Dakota Law Struck Down

The 340B drug discount program faced multiple converging pressures this week. Eli Lilly threatened to pull 340B discounts from hospitals over an ongoing claims data dispute, prompting hospital groups to demand HRSA intervention to enforce the program’s statutory requirements. HRSA’s 340B rebate model pilot—under which manufacturers would issue rebates rather than upfront discounts—drew sharply opposed feedback from hospitals (which oppose the model) and drugmakers (which support it). HFMA reported that hospital and insurer disagreement over rebate model costs is becoming a broader payer-provider fault line. On the legal front, a federal judge permanently blocked North Dakota’s 340B contract pharmacy law as unconstitutional, the latest in a string of state-law rulings that have largely sided with manufacturers. Together, the developments highlight the structural instability of the program’s rebate, contract-pharmacy, and enforcement architectures.

• Hospitals Demand HRSA Intervene After Eli Lilly Threatens to Pull 340B Discounts
• Hospitals and Insurers Clash Over 340B Rebate Model Costs
• HRSA 340B Rebate Pilot Query Splits Hospitals, Drugmakers
• Federal Judge Permanently Blocks North Dakota 340B Contract Pharmacy Law as Unconstitutional

Tags: #HOSPITAL #DRUG #PAYER

Edwards Lifesciences Q1 Strength Coincides with Launch of RAPID Pathway for Breakthrough Cardiology Devices

Edwards Lifesciences raised its 2026 sales guidance after a Q1 in which Transcatheter Aortic Valve Replacement (TAVR) sales surged ahead of expectations, with company executives citing continued momentum in transcatheter mitral and tricuspid programs. In a separate but related development, on April 23 the Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to compress the historical year-or-more wait between FDA market authorization and Medicare national coverage determinations to as soon as two months for eligible Class II and Class III breakthrough devices. The Trump administration described the move as part of a broader push to speed Medicare coverage for breakthrough cardiology devices specifically, citing structural heart, electrophysiology, and heart-failure-monitoring product categories where the gap between FDA approval and CMS coverage has historically been longest. The two developments are linked: faster Medicare coverage for breakthrough cardiology devices is a structural tailwind for Edwards and its structural-heart competitors at exactly the moment Edwards is reporting a strong commercial quarter. Notably, CMS is pausing the existing Transitional Coverage for Emerging Technologies (TCET) pathway for new candidates as it focuses on RAPID implementation.

Sources: MedTech Dive, Cardiovascular Business, CMS, Cardiovascular Business

Tags: #DEVICE #PAYER #PROVIDER

CMS Medicare Provider Directory Database Exposed Doctors’ Social Security Numbers

Multiple outlets reported that the CMS Medicare Provider Directory Database publicly exposed Social Security Numbers for an undisclosed number of physicians, raising significant data security and privacy concerns. The exposure was discovered after individual physicians noticed their personal data in publicly downloadable agency files. CMS confirmed it has removed the affected data and is reviewing how SSNs entered a public-facing dataset. The incident is likely to prompt congressional oversight scrutiny and could affect physician willingness to participate in Medicare directory updates pending stronger data handling controls.

Sources: Becker’s Hospital Review, MedPage Today, POLITICO, The Hill

Tags: #PROVIDER

CMMI ACCESS Model Draws 150 Digital Health Companies in First Cohort, with Headwinds Ahead

Fierce Healthcare’s deeper dive into the CMS Innovation Center (CMMI) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model details that 150 digital health companies are participating in the first cohort. Many participants describe the model as an inflection point for connected care and as an opportunity to demonstrate that AI-enabled medical services can move the needle on cost and quality for chronic conditions including musculoskeletal pain, behavioral health, prediabetes, and chronic kidney disease. Significant headwinds remain, including health plan adoption uncertainty and operational complexity for digital health vendors not previously contracting with Medicare.

Source: Fierce Healthcare

Tags: #PAYER #PROVIDER

Food and Drug Administration (FDA)

TAVR and Cardiac Surgery Outcomes Research: Multiple Studies Inform the Practice Standard

A cluster of new outcomes data continued to refine the clinical evidence base around Transcatheter Aortic Valve Replacement (TAVR) and adjacent cardiac procedures. Real-world data showed that women live longer than men after TAVR, and a separate study found apixaban outperformed rivaroxaban for post-TAVR atrial fibrillation. A study reported that semaglutide and other GLP-1 agonists were linked to better outcomes for patients undergoing TAVR and percutaneous coronary intervention (PCI). On the negative side, embolic protection devices designed to prevent stroke during TAVR failed to show meaningful clinical impact in new data. A redo TAVR analysis found supra-annular and intra-annular valves produced comparable outcomes; fibrosis was identified as a possible predictor of aortic stenosis outcomes. In structural heart adjacencies, paravalvular leak after Transcatheter Tricuspid Valve Replacement (TTVR) was linked to lower survival, redo surgery beat transcatheter treatment for failed bioprosthetic mitral valves at five years, and early Surgical Aortic Valve Replacement (SAVR) in asymptomatic heart patients was associated with long-term benefits. Edwards Lifesciences shared 10-year Resilia tissue durability data; an off-the-shelf coronary artery bypass graft (CABG) conduit showed promise in a first-in-human study; the FDA approved two new implantable cardiac devices from Biotronik.

• Women Live Longer Than Men After TAVR, Real-World Data Show
• Popular Weight Loss Drug Linked to Key Benefits for Patients Undergoing TAVR, PCI
• Stroke Prevention Devices for TAVR Fail to Make an Impact
• Redo TAVR: Supra-Annular and Intra-Annular Valves Linked to Comparable Outcomes
• Fibrosis May Predict Outcomes in Aortic Stenosis
• Paravalvular Leak After TTVR Linked to Lower Survival Rates
• Early SAVR in Asymptomatic Heart Patients Linked to Long-Term Benefits
• FDA-Approved Surgical Aortic Valve Implanted for First Time in US
• Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
• When Bioprosthetic Mitral Valves Fail: Redo Surgery Bests Transcatheter Treatment After 5 Years
• New Off-the-Shelf Conduit for CABG Shows Promise in First-in-Human Study
• FDA Approves Two Implantable Cardiac Devices from Biotronik

Tags: #DEVICE #PROVIDER

Heart Rhythm 2026: Pulsed Field Ablation Dominates as Medtronic Wins Sphere-9 Breakthrough Designation

The Heart Rhythm Society 2026 Annual Meeting underscored Pulsed Field Ablation (PFA) as the dominant theme in electrophysiology, with new comparative data and conference programming concentrated on the technology. Outgoing HRS President Mina Chung discussed CPR, PFA, and future priorities for the field. Medtronic, Boston Scientific, and Abbott all reported positive PFA-related data on their respective platforms, signaling intensifying competition in the space. Medtronic separately received FDA Breakthrough Designation for its Sphere-9 ventricular tachycardia catheter, which would extend the company’s PFA platform into a more complex arrhythmia indication. The conference also featured key cardiac device data across multiple structural and rhythm management categories, with MedTech Dive’s four-studies-to-know summary capturing the most clinically significant readouts.

• Key Cardiac Device Data from Heart Rhythm Society 2026 Annual Meeting
• Pulsed Field Ablation Dominates Electrophysiology Trends at Heart Rhythm 2026
• Heart Rhythm 2026: Outgoing HRS President Mina Chung Discusses CPR, PFA, and Future Priorities
• Medtronic Receives FDA Breakthrough Designation for Sphere-9 Ventricular Tachycardia Catheter

Tags: #DEVICE #PROVIDER

FDA Approves Next-Generation Medtronic Mitral Replacement Valve

The Food and Drug Administration (FDA) approved the next-generation Medtronic mitral replacement valve, expanding the company’s structural heart portfolio. Multiple outlets reported that the approval reflects continued investment in the transcatheter mitral space, where Edwards Lifesciences and Abbott also have active programs. The approval is expected to intensify near-term competition in the structural heart device market and extends the field of FDA-cleared options for clinicians treating degenerative mitral valve disease.

Sources: Cardiovascular Business, MedTech Dive

Tags: #DEVICE

FDA Regulatory Modernization Push: Real-Time Trial Review, MDUFA VI Agreement, and Transparency Fights

The Food and Drug Administration (FDA) advanced multiple regulatory modernization efforts. The agency unveiled a real-time clinical trial review program with AI assistance, naming AstraZeneca and Amgen as the first participants in a pilot designed to gather and review trial endpoint data as it is generated rather than at submission. FDA and industry reached an agreement in principle on the Medical Device User Fee Amendments VI (MDUFA VI) program, with officials at the 2026 MedCon conference describing the timeline as a record. The agreement keeps user fee funding largely flat while focusing on strengthening review fundamentals, transparency, and accountability. Center for Devices and Radiological Health (CDRH) Director Michelle Tarver reported that the center authorized 124 novel medical devices in 2025, the third-highest annual total in the center’s history. Other regulatory modernization moves included a proposed FDA Form 483 response draft guidance that industry warns could create new friction for manufacturers, a citizen petition challenging FDA’s plan to publish Complete Response Letters in real time, a proposed withdrawal of a vasculitis drug previously approved on data the agency now describes as manipulated, and a UK-US framework for shared medical device approvals.

• FDA Launches Real-Time Clinical Trial Review Using AI, with AstraZeneca and Amgen First to Participate
• FDA, Industry Reach Agreement in Principle on MDUFA VI
• CDRH Director: 124 Novel Devices Authorized in 2025
• FDA Form 483 Response Draft Guidance Creates Potential Friction for Manufacturers
• Citizen Petition Challenges FDA Real-Time Publication of Complete Response Letters
• FDA Proposes Withdrawal of Vasculitis Drug Approved on ‘Manipulated’ Data
• UK and US Set Path to Shared Medical Device Approvals

Tags: #DEVICE #DRUG

Supreme Court Temporarily Restores Mail-Order Mifepristone Access After Fifth Circuit Ban

On May 4, the Supreme Court issued an order from Justice Samuel Alito temporarily pausing a Fifth Circuit Court of Appeals ruling that had blocked mail-order distribution of mifepristone, restoring access while the full Court considers the case. The Fifth Circuit ruling, issued the prior week, had reinstated pre-2016 FDA restrictions on the abortion medication, including in-person dispensing requirements. The temporary restoration is procedural and does not resolve the underlying legal challenge to FDA’s regulatory authority over the medication, which involves long-running questions about agency discretion, REMS requirements, and judicial review of drug approvals.

Sources: STAT News, POLITICO, Healthcare Dive, The Hill, Fierce Healthcare

Tags: #DRUG #PATIENT

Department of Health and Human Services (HHS)

Trump Withdraws Casey Means Surgeon General Nomination, Names Nicole Saphier

President Trump withdrew the surgeon general nomination of Casey Means after Senator Bill Cassidy (R-LA), chair of the Senate HELP Committee, signaled he would not advance the nomination, citing concerns about Means’ qualifications and her positions on certain MAHA platform items. The administration moved quickly to nominate Fox News medical contributor Dr. Nicole Saphier, a radiologist at Memorial Sloan Kettering Cancer Center. The replacement drew immediate criticism from MAHA-aligned figures who had supported Means. Senator Lisa Murkowski (R-AK) signaled openness to Saphier but said she wanted to review the new nominee’s record on vaccines and public health policy. The episode is the latest example of internal divisions within the administration’s health policy coalition, with MAHA voters frustrated by the swap and traditional Republicans expressing relief that the previous nominee was withdrawn.

Sources: STAT News, New York Times, POLITICO, The Hill, Fierce Healthcare, MedPage Today

Tags: #POLICY

RFK Jr. Vaccine Policy Fight Escalates: Gavi Hold, ACIP Hep B Revisions, CDC Messaging Concerns

HHS Secretary Robert F. Kennedy Jr.’s vaccine policy agenda escalated on multiple fronts. Kennedy is holding up $600 million in congressionally appropriated vaccine funding for Gavi, the international vaccine alliance, citing concerns about thimerosal-containing products. The Advisory Committee on Immunization Practices (ACIP) is undertaking revisions to the hepatitis B vaccine schedule under Kennedy’s direction. New CDC messaging on vaccines and autism may be increasing vaccine hesitancy according to a recent survey, raising concerns among public health experts about long-term vaccination rates. The federal autism advisory committee held its first meeting and focused on “profound autism” as a new operational definition. The House Appropriations Committee advanced the FDA budget despite member concerns about vaccine policy direction. Together, the developments mark an unusually active week for federal vaccine policy and represent a coordinated pressure campaign on legacy CDC and FDA vaccine frameworks.

• RFK Jr. Holds Up $600M in Congressional Vaccine Funding for Gavi, the Vaccine Alliance
• New CDC Messaging on Vaccines and Autism May Be Increasing Vaccine Hesitancy, Survey Finds
• In First Meeting, Federal Autism Committee Focuses on ‘Profound Autism’
• House Approps Committee Advances FDA Budget Despite Vaccine Concerns

Tags: #PATIENT #PROVIDER #POLICY

HHS Pressures Hospitals and Nursing Homes on Patient Nutrition, Threatens Funding Withholds

HHS issued new guidance pressuring hospitals and nursing homes to overhaul patient meal programs, with the agency threatening to withhold federal funding from facilities that fail to comply with revised dietary standards. Multiple outlets reported that the move follows Secretary Kennedy’s broader MAHA-aligned push to reorient federal health policy around nutrition, with a particular focus on processed foods, sugar, and seed oils in institutional meals. Hospitals are evaluating compliance pathways and operational costs, with some industry groups raising concerns about reimbursement implications and the practical timeline for menu redesign.

Sources: KFF Health News, Becker’s Hospital Review

Tags: #HOSPITAL #PATIENT

HHS Operational Pressures: Conflicts of Interest, Hiring Bottlenecks, and Researcher Departures

Operational pressures inside HHS continued to mount. STAT and the New York Times reported on scrutiny of Secretary Kennedy’s transparency record and conflicts of interest within HHS, including reports that a top adviser to Kennedy had more than $25 million in undisclosed investments. Insider reporting from Inside Health Policy described how RFK Jr.’s plan to add 12,000 new HHS staffers is colliding with employee accounts that even routine hiring is stalling. STAT’s policy survey found that immigration policy changes are driving foreign researchers to leave the United States or decline to come, raising concerns about long-term biomedical research workforce pipelines. Separately, former NIH adviser David Morens, an associate of Anthony Fauci, was indicted on charges of concealing emails and avoiding records requests, adding another legal thread to the broader pandemic-era oversight environment.

• Scrutiny Mounts Over Kennedy’s Transparency Record and Conflicts of Interest Within HHS
• RFK Jr. Wants 12,000 New HHS Staffers; Employees Say Even Routine Hiring Is a Challenge
• Immigration Policy Changes Are Driving Foreign Researchers to Leave the U.S. or Forgo Coming
• Fauci Adviser David Morens Indicted on Charges of Concealing Emails, Avoiding Records Requests

Tags: #POLICY #PROVIDER

Heard on the Hill

House Ways and Means Hearing Puts Hospital Affordability Under Bipartisan Spotlight

The House Ways and Means Committee held a high-profile hearing on hospital affordability, with CEOs of HCA Healthcare, CommonSpirit Health, and other major systems facing pointed questioning from both Republican and Democratic members. STAT News characterized the hearing as letting executives “get off easy,” while The Hill reported that House Republicans took aim at hospital CEOs over the affordability crisis. MedPage Today and Becker’s Hospital Review described an unusually adversarial tone—at one point a member compared hospital profitability to Disney’s, framing the systems as “more lucrative” than the entertainment company. The hearing covered prior authorization friction, billing transparency, charity care obligations, and the link between consolidation and prices. Background coverage from Axios and Modern Healthcare noted that hospitals serving the sickest patients are closing at an accelerating rate, adding policy urgency to the affordability conversation.

Sources: STAT News, The Hill, MedPage Today, Becker’s Hospital Review, Axios

Tags: #HOSPITAL #PAYER

Health System CEOs Concede ‘Rational Reworking’ of Site-Neutral Payments at House Hearing

At the House Ways and Means hospital affordability hearing, the CEOs of HCA Healthcare, CommonSpirit Health, and other major systems publicly conceded openness to a “rational reworking” of site-neutral payment policy—a notable shift from longstanding hospital lobby opposition. Site-neutral proposals would equalize Medicare payments for the same services delivered in hospital outpatient departments versus physician offices and ambulatory surgery centers, an alignment that would reduce hospital revenue. HFMA’s coverage characterized the exchange as the most significant softening of provider opposition in years and could accelerate site-neutral provisions in upcoming Medicare legislation. Whether the concession translates into specific support for any particular policy proposal—or simply a willingness to negotiate—remains an open question and will be tested in subsequent committee markups.

Sources: Fierce Healthcare, HFMA, Healthcare Dive

Tags: #HOSPITAL #PAYER

ACA Enrollment Drops Sharply as Enhanced Premium Tax Credits Expire

Affordable Care Act (ACA) Marketplace enrollment for 2026 declined sharply following the expiration of enhanced premium tax credits put in place during the pandemic. The New York Times reported that the early enrollment period showed retention concerns, with substantial drops in some state-based marketplaces. Health Management Associates analyzed the early signals and described 2026 as a “pivotal” enrollment cycle, with the combination of subsidy reductions and HR 1’s marketplace tax repayment changes likely to widen the uninsured population. The enrollment shortfall has direct hospital revenue implications and is one driver of the safety-net hospital pressures discussed at this week’s House hospital affordability hearing.

Sources: New York Times, Health Management Associates

Tags: #PAYER #PATIENT #HOSPITAL

Republicans See High-Deductible and High-Risk Plans as Future of Health Insurance

POLITICO reported that Republican policymakers and aligned think tanks are increasingly framing high-deductible health plans, health savings accounts, and revived high-risk pool structures as the future of health insurance, particularly for non-group and small-group markets. The framing represents a significant shift in conservative health policy emphasis and has implications for ACA Marketplace design, individual market regulation, and federal reinsurance proposals. Industry stakeholders expressed both interest in the consumer-directed design and concerns about adverse selection, affordability for lower-income enrollees, and interaction with existing protections for pre-existing conditions.

Source: POLITICO

Tags: #PAYER #PATIENT

Education Department Finalizes Industry-Opposed $50,000 Annual Cap on Federal Student Loans for Medical School

The Department of Education finalized a $50,000 annual cap on federal student loans for medical school over the objections of medical education and physician industry groups. The cap is intended to constrain federal loan exposure and limit cost growth in graduate medical education, but critics argue it will deepen existing affordability barriers to medical training, particularly for students from lower-income backgrounds and those entering lower-paying specialties. The American Association of Medical Colleges and other groups have warned the rule could exacerbate physician workforce shortages, particularly in primary care and rural settings where loan forgiveness programs are most needed.

Source: Inside Health Policy

Tags: #PROVIDER

Visa Program Delays Threaten Placement of Hundreds of Foreign-Trained Doctors in Underserved Areas

Delays in the Conrad 30 J-1 visa waiver program and broader visa processing slowdowns are threatening the placement of hundreds of foreign-trained physicians who match into U.S. residency programs and rural underserved-area positions. KFF Health News and MedPage Today documented that the delays risk leaving rural and FQHC sites without anticipated physician coverage, with downstream consequences for access to care in HRSA-designated shortage areas. State officials and program directors are calling for expedited federal action.

Sources: KFF Health News, MedPage Today

Tags: #PROVIDER

Notable Notes

Drug Pricing Landscape: TrumpRx Expands, MFN Reconciliation Talks, PBM Push, SCOTUS Skinny Labeling

Drug pricing news ran on multiple parallel tracks. Johnson & Johnson and Humana expanded drug pricing programs through the TrumpRx direct-to-consumer platform and a partnership with Mark Cuban’s Cost Plus Drugs, with both initiatives aimed at lowering out-of-pocket costs. CMS Administrator Mehmet Oz signaled that codifying Most Favored Nation (MFN) drug pricing is part of ongoing reconciliation talks, with lawmakers weighing the policy concerns and downstream implementation risk. Inside Health Policy reported that Democrats and employers are aligning on strengthening the Department of Labor’s pending PBM disclosure rule, while a broader regulatory push on PBMs continues across federal kickbacks legislation, Labor Department transparency rules, and state-level efforts. Pharmacy Benefit Managers (PBMs) are leaning on private-label biosimilars to manage drug costs, though the strategy faces questions about whether savings reach plan sponsors and patients. The Supreme Court heard oral arguments in a closely watched skinny labeling case that could reshape generic drug market entry.

• J&J and Humana Expand Drug Pricing Programs Through TrumpRx and Cost Plus Partnership
• Oz Signals Codifying MFN Part of Reconciliation Talks, Lawmakers Weigh Policy Concerns
• Democrats and Employers Align on Strengthening DOL Proposed PBM Disclosure Rule
• PBMs Lean on Private Label Biosimilars to Cut Drug Costs
• Humana’s CenterWell, Mark Cuban Cost Plus Drugs Partner to Tackle Employers’ Drug Costs
• STAT+ Pharmalittle: Warnings Over Trump’s MFN Plan, Purdue Pharma Sentencing

Tags: #DRUG #PAYER